Compare GSK plc (GSK) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs MasTec Inc — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while MasTec Inc trades at $343.46 (market cap $28.27B). The key difference: GSK plc is far larger — about 3.6× MasTec Inc's market cap, and GSK plc pays a 3.49% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| GSK | MTZ | |
|---|---|---|
Market Cap | $101.34B | $28.27B |
Sector | Health | Technology |
52-Week High | $61.18 | $437.51 |
52-Week Low | $36.20 | $172.51 |
Enterprise Value | $121.95B | $31.01B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
MasTec (MTZ) trades at $343.18, down 6% in the last session, amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 earnings beating estimates by 40.6% and a record $20.3 billion backlog. Recent news highlights a $1.65 billion acquisition of The Superior Group to expand AI data center infrastructure capabilities, driving investor optimism despite near-term price weakness.
Outlook remains positive with 88.9% analyst buy ratings and a $481.77 consensus target implying 40% upside. Key risks include execution of large acquisitions and integration challenges, while growth is supported by infrastructure spending trends in power, data centers, and clean energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
